Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

IGC Pharma (IGC) EBITDA Margin (2016 - 2025)

IGC Pharma has reported EBITDA Margin over the past 16 years, most recently at 963.35% for Q3 2025.

  • Quarterly EBITDA Margin fell 54296.0% to 963.35% in Q3 2025 from the year-ago period, while the trailing twelve-month figure was 585.9% through Sep 2025, up 47640.0% year-over-year, with the annual reading at 562.63% for FY2025, 40644.0% up from the prior year.
  • EBITDA Margin was 963.35% for Q3 2025 at IGC Pharma, down from 488.41% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 360.91% in Q1 2025 and troughed at 7721.43% in Q3 2021.
  • The 5-year median for EBITDA Margin is 977.29% (2024), against an average of 1871.7%.
  • The largest YoY upside for EBITDA Margin was 808621bps in 2021 against a maximum downside of -650943bps in 2021.
  • A 5-year view of EBITDA Margin shows it stood at 1622.54% in 2021, then soared by 57bps to 695.78% in 2022, then tumbled by -292bps to 2730.88% in 2023, then skyrocketed by 74bps to 718.68% in 2024, then tumbled by -34bps to 963.35% in 2025.
  • Per Business Quant, the three most recent readings for IGC's EBITDA Margin are 963.35% (Q3 2025), 488.41% (Q2 2025), and 360.91% (Q1 2025).